Active Surveillance (n = 99) | Radical prostatectomy (n = 99) | External-beam radiotherapy (n = 99) | Brachytherapy (n = 99) | p-value | |
---|---|---|---|---|---|
Risk group* | |||||
Low risk | 74 (74.7%) | 74 (74.7%) | 74 (74.7%) | 74 (74.7%) | 1.000 |
Intermediate risk | 25 (25.3%) | 25 (25.3%) | 25 (25.3%) | 25 (25.3%) | |
Age at HRQoL survey, mean (SD), years | 70.6 (5.4) | 68.2 (5.4) | 73.2 (5.3) | 71.9 (5.0) | 0.065 |
Elapsed time from treatment selection to HRQoL survey, years | |||||
Mean (SD) | 2.6 (1.5) | 3.1 (1.9) | 2.8 (1.9) | 2.9 (1.7) | 0.434 |
Median [IQR] | 2.4 [1.4–3.6] | 3.1 [1.0–4.1] | 2.0 [1.0–4.1] | 3.0 [1.0–4.1] | |
Minimum - Maximum | 0.53–7.32 | 0.45–8.32 | 0.46–8.32 | 0.48–7.06 | |
PSA, mean (SD), ng/ml | 6.8 (2.9) | 7.3 (2.8) | 7.7 (3.0) | 7.6 (2.6) | 0.087 |
PSA ≤ 10 | 84 (84.8%) | 88 (89.8%) | 84 (84.8%) | 85 (85.9%) | 0.709 |
PSA > 10 | 15 (15.2%) | 10 (10.2%) | 15 (15.2%) | 14 (14.1%) | |
Gleason score | |||||
2–5 | 0 | 12 (12.1%) | 30 (30.3%) | 28 (28.2%) | < 0.001a,b,c |
6 | 90 (90.9%) | 72 (72.7%) | 53 (53.5%) | 64 (64.6%) | |
7 (3 + 4) | 9 (9.1%) | 15 (15.2%) | 16 (16.2%) | 7 (7.1%) | |
Clinical stage | |||||
T1a-T1c | 78 (78.8%) | 71 (71.7%) | 68 (68.7%) | 80 (80.3%) | 0.157 |
T2a-T2b | 21 (21.2%) | 28 (28.3%) | 31 (31.3%) | 19 (19.2%) | |
Comorbidities | |||||
Osteoarthritis or Rheumatism | 31 (43.1%) | 44 (48.9%) | 40 (50.6%) | 0.623 | |
High blood pressure | 26 (36.1%) | 33 (36.7%) | 33 (41.8%) | 0.723 | |
Depression or Mental disorders | 13 (18.1%) | 12 (13.3%) | 17 (21.5%) | 0.370 | |
Chronic respiratory diseases | 7 (9.7%) | 17 (18.9%) | 16 (20.3%) | 0.168 | |
Ischemic heart disease | 6 (8.3%) | 16 (17.8%) | 11 (13.9%) | 0.220 | |
Diabetes mellitus | 8 (11.1%) | 13 (14.4%) | 10 (12.7%) | 0.818 | |
Stroke | 2 (2.8%) | 3 (3.3%) | 4 (5.1%) | 0.737 |